Introduction:

In recent years, modern biotechnology represented by genetic engineering and cell engineering has developed rapidly, major technologies such as the Human Genome Project have made breakthroughs, and the industrialization of biomedicine has accelerated significantly. With the favorable support of the national policy on innovative drugs, China's biomedical R&D investment will also continue to increase. As one of China's strategic emerging industries, the biopharmaceutical industry has developed rapidly and accumulated tremendous momentum. In drug development, the verified target/structure/indication has become a red sea, and the "inner roll" of the industry will become a shackle. Only the source innovation can break through the tight encirclement. Since the development of the biomedical industry, it has entered the clinical stage by a big step. In the face of the transformation trend of more and more pharmaceutical enterprises simultaneously laying out "large and small molecules", innovative large and small molecule drugs are both guided by clinical value and aim to meet the clinical needs of patients who have not been met. The global biopharmaceutical market shows a strong growth trend that is far faster than the global economic growth rate. The biopharmaceutical industry is ushering in a golden age of development driven by both technological progress and demand growth. Especially since the COVID-19, the global public health system has faced unprecedented challenges. Countries have increased their deployment of biomedicine, while increasing R&D investment for infectious diseases. And China

In the process of prevention and control of this epidemic, we have made leading achievements that attract global attention, and further promoted the rapid development of domestic biomedical industry.

2022 Cell Industry Conference The 10th (Wuhan) Cell and Tumor Precision Medical Summit Forum 2022 and Wuhan Biomedical Innovation and Development Summit will be held in Wuhan in November. This summit will set up exhibition areas and multiple sub forums, closely focusing on topics such as cell therapy research and development and industrialization, autoimmunity and tumor immunity, gene therapy and oncolytic virus, innovative drug development and technological innovation, antibody drug development and target screening, A number of authoritative experts and industry leaders from the national drug evaluation and supervision institutions, scientific research institutes, medical institutions, innovative pharmaceutical enterprises, bio therapy, biotechnology and service enterprises, upstream and downstream enterprises of the industrial chain, industrial parks, investment institutions, industry associations, etc. are specially invited to share and discuss, so as to promote the full speed development of the industry.

Who will sponsor

Preclinical cell research and clinical application transformation, cell storage and treatment, tumor immunotherapy, cell and gene therapy, investment strategy of biological innovative drug industry, frontier technology of biological innovative drugs, CDMO production process of biological drugs, preclinical research and registration application of biological drugs, single cell multiomics, single cell sequencing, isolation and detection of extracellular vesicles, gene therapy and oncolytic virus, solid tumor treatment and drug development TIL cell therapy, CAR-T/TCR-T cell therapy, universal CAR-T cell immunotherapy γδ T cells, solid tumor regenerative medicine, single cell technology, space-time transcriptomics and multiomics technology, flow cytometry, adeno-associated virus (AAV), gene vector, lentivirus, adenovirus, cell therapy product registration and application, 3D cell culture, organ like culture, biological 3D printer, 3D cell imaging, mRNA vaccine/drug research and development, innovative drug research and development, PD-1/L1 drug, early screening and early diagnosis, tumor metastasis and recurrence monitoring Molecular targeted treatment of tumors, clinical research and disease treatment of exosomes, targeted drug use, genome science and technology led by NGS technology, digital PCR, mass spectrometry, PCR derivative technology, industrialization process of precision medicine, molecular diagnosis, gene therapy, nucleic acid drugs, gene sequencing, liquid biopsy and early screening of tumors, full cycle of tumors, clinical treatment of tumors, genomics, biomarkers, translational medicine, biological products Serum free culture media, reagents, instruments, consumables, CRO, CMO, CDMO, bio information big data, AI auxiliary diagnosis, in vitro diagnosis, antibody, MALBAC technique, Crispr/Cas9 and gene editing technology, laboratory management and control, clinical application and research, tumor drug gene detection, policy supervision, histology big data, industrial cluster booth and forum sponsorship

Sponsors and speech fees

Package 1: 2 open booths+40 minutes of speech+the third cover of the electronic edition of the conference journal+RMB 100000 for data in the bag

Package 2: 1 open booth+30 minute speech+color page of the electronic edition of the conference catalogue 1P RMB 50000

Package 3: 1 open booth+20 minutes of speech+the electronic version of the conference catalogue color page 1P RMB 40000

Package 4: 20 minute speech RMB 20000

Package V: 1 open booth RMB 22800

Package 6: RMB 2000 per square meter for bare space booth

Charging standard for audience representatives

Register RMB 600 per person before November 1, 2022; Registered RMB 800 per person after November 1 (Wuhan);

Group registration: 10% discount for more than 3 people ?

The expenses include: conference materials, admission qualification, PPT of authorized teachers, lunch, tea break, etc.

• Company:Shanghai Shunzhan Exhibition Service Co., Ltd
• Truename:Wu Tong
• Mobile:18721130652
• Address:Wuhan Living Room (Wuhan Polar Ocean World), No. 8 Hongtu Road, Jinyintan Avenue, Dongxihu District, Wuhan City, Hubei Province

The information on this site comes from the network and related members, and the website has done its duty to review it. Due to the uncontrollability of the process of organizing the exhibition, some of the exhibition information in the station may change the subject matter, Extending or cancelling the event, please exhibitors and visitors must check with each other again before exhibiting! All the exhibitions in this site are not hosted/co-organized or organized, if there are any disputes during the exhibition, please hold the main responsibility of the exhibition organization! QQ Email: 523138820@qq.com WeChat: 523138820 Mobile: 15313206870